Next Article in Journal
The Autophagy Status of Cancer Stem Cells in Gliobastoma Multiforme: From Cancer Promotion to Therapeutic Strategies
Next Article in Special Issue
Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection
Previous Article in Journal
Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?
Previous Article in Special Issue
Genetic Deletion or Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Cardiac Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation
Open AccessReview

Hurdles to Cardioprotection in the Critically Ill

1
Critical Care Research Group, The Prince Charles Hospital, Chermside 4032, Australia
2
Faculty of Medicine, University of Queensland, Chermside 4032, Australia
3
Science and Engineering Faculty, Queensland University of Technology, Chermside 4032, Australia
4
School of Medical Science, Griffith University, Southport 4222, Australia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(15), 3823; https://doi.org/10.3390/ijms20153823
Received: 5 July 2019 / Revised: 26 July 2019 / Accepted: 3 August 2019 / Published: 5 August 2019
Cardiovascular disease is the largest contributor to worldwide mortality, and the deleterious impact of heart failure (HF) is projected to grow exponentially in the future. As heart transplantation (HTx) is the only effective treatment for end-stage HF, development of mechanical circulatory support (MCS) technology has unveiled additional therapeutic options for refractory cardiac disease. Unfortunately, despite both MCS and HTx being quintessential treatments for significant cardiac impairment, associated morbidity and mortality remain high. MCS technology continues to evolve, but is associated with numerous disturbances to cardiac function (e.g., oxidative damage, arrhythmias). Following MCS intervention, HTx is frequently the destination option for survival of critically ill cardiac patients. While effective, donor hearts are scarce, thus limiting HTx to few qualifying patients, and HTx remains correlated with substantial post-HTx complications. While MCS and HTx are vital to survival of critically ill cardiac patients, cardioprotective strategies to improve outcomes from these treatments are highly desirable. Accordingly, this review summarizes the current status of MCS and HTx in the clinic, and the associated cardiac complications inherent to these treatments. Furthermore, we detail current research being undertaken to improve cardiac outcomes following MCS/HTx, and important considerations for reducing the significant morbidity and mortality associated with these necessary treatment strategies. View Full-Text
Keywords: heart failure; heart transplantation; mechanical circulatory support; cardioprotection heart failure; heart transplantation; mechanical circulatory support; cardioprotection
Show Figures

Figure 1

MDPI and ACS Style

See Hoe, L.E.; Bartnikowski, N.; Wells, M.A.; Suen, J.Y.; Fraser, J.F. Hurdles to Cardioprotection in the Critically Ill. Int. J. Mol. Sci. 2019, 20, 3823.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop